CA Patent

CA3090070C — Method of synthesizing thyroid hormone analogs and polymorphs thereof

Assigned to F Hoffmann La Roche AG · Expires 2023-01-24 · 3y expired

What this patent protects

Abstract The disclosure describes a morphic form of 2-(3,5-dichloro-44(5-isopropy1-6- oxo- 1,6-dihydropyridazin-3-yl)oxy)pheny1)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4- triazine-6- carbonitrile ("Compound A"), wherein the morphic form is a hydrate. Also described is a pharmac…

USPTO Abstract

Abstract The disclosure describes a morphic form of 2-(3,5-dichloro-44(5-isopropy1-6- oxo- 1,6-dihydropyridazin-3-yl)oxy)pheny1)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4- triazine-6- carbonitrile ("Compound A"), wherein the morphic form is a hydrate. Also described is a pharmaceutical composition comprising the morphic form and a pharmaceutically acceptable carrier. Date Recue/Date Received 2020-08-14

Drugs covered by this patent

Patent Metadata

Patent number
CA3090070C
Jurisdiction
CA
Classification
—
Expires
2023-01-24
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.